Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, 45363, Indonesia.
Department of Pharmaceutics, Faculty of Pharmacy, Minia University, Minia, 61519, Egypt.
Int J Nanomedicine. 2024 May 30;19:5021-5044. doi: 10.2147/IJN.S469572. eCollection 2024.
Nanoparticle systems integrating alginate and chitosan emerge as a promising avenue to tackle challenges in leveraging the potency of pharmacological active agents. Owing to their intrinsic properties as polysaccharides, alginate and chitosan, exhibit remarkable biocompatibility, rendering them conducive to bodily integration. By downsizing drug particles to the nano-scale, the system enhances drug solubility in aqueous environments by augmenting surface area. Additionally, the system orchestrates extended drug release kinetics, aligning well with the exigencies of chronic drug release requisite for antibacterial therapeutics. A thorough scrutiny of existing literature underscores a wealth of evidence supporting the utilization of the alginate-chitosan nanoparticle system for antibacterial agent delivery. Literature reviews present abundant evidence of the utilization of nanoparticle systems based on a combination of alginate and chitosan for antibacterial agent delivery. Various experiments demonstrate enhanced antibacterial efficacy, including an increase in the inhibitory zone diameter, improvement in the minimum inhibitory concentration, and an enhancement in the bacterial reduction rate. This enhancement in efficacy occurs due to mechanisms involving increased solubility resulting from particle size reduction, prolonged release effects, and enhanced selectivity towards bacterial cell walls, stemming from ionic interactions between positively charged particles and teichoic acid on bacterial cell walls. However, clinical studies remain limited, and there are currently no marketed antibacterial drugs utilizing this system. Hence, expediting clinical efficacy validation is crucial to maximize its benefits promptly.
将海藻酸钠和壳聚糖整合在一起的纳米颗粒系统为克服药理学活性药物的功效利用挑战提供了一个很有前景的途径。由于其作为多糖的固有特性，海藻酸钠和壳聚糖具有显著的生物相容性，有利于与身体融合。通过将药物颗粒缩小到纳米级，该系统通过增加表面积来提高药物在水相环境中的溶解度。此外，该系统还可以控制药物的释放动力学，与抗菌治疗所需的慢性药物释放的要求相吻合。对现有文献的全面审查强调了大量证据支持利用海藻酸钠-壳聚糖纳米颗粒系统来输送抗菌剂。文献综述提供了大量证据表明，利用基于海藻酸钠和壳聚糖的纳米颗粒系统可以输送抗菌剂。各种实验表明，该系统增强了抗菌功效，包括抑菌圈直径的增加、最小抑菌浓度的改善以及细菌减少率的提高。这种功效的增强是由于颗粒尺寸减小导致的溶解度增加、释放效果延长以及由于带正电荷的颗粒与细菌细胞壁上的磷壁酸之间的离子相互作用而增强的对细菌细胞壁的选择性等机制所致。然而，临床研究仍然有限，目前没有利用该系统的上市抗菌药物。因此，加快临床疗效验证至关重要，以便尽快发挥其优势。
